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remain at year 2013 level, and these were then combined with official population 
forecasts. Results: Altogether 160,952 individuals (81% of all inhabitants) had at 
least one healthcare contact during the follow up. Primary and secondary healthcare 
services had been used by 155,631 and 59,589 patients, respectively. The average 
annual cost per patient was 1,853€ . The average cost in primary and secondary 
healthcare was 808€ and 2,895€ , respectively. Variation was wide across the dif-
ferent ages (Primary healthcare, range: 346€ –5,645€ ; Secondary healthcare, range: 
1,282€ –4,474€ ). Due to aging of the population only, according to the future projec-
tions, in the year 2025, the total primary healthcare costs are 21% and secondary 
healthcare costs 14% higher than in 2013. ConClusions: With respect to costs, 
aging of the population affects primary healthcare more than specialized health-
care. Thus, the healthcare utilization should be regarded as one entity taking into 
account both primary and secondary healthcare services. If the overall treatment 
process, from primary care to secondary care and sometimes back to primary care, 
is not taken in to account, this will lead to suboptimal decision making.
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objeCtives: To describe health service utilization (HSU) patterns of dengue cases 
by age, severity of illness, and healthcare sector, in Brazil during an epidemic den-
gue transmission period. Methods: A multicenter cohort study was conducted 
in 2012-2013 at four Brazilian endemic regions. Patients were ascertained in units 
and hospitals from both public and private sectors. Data collection was performed 
by interviewing 15-20 days after the onset of symptoms and review of medical 
records of hospitalized patients. HSU specific information included: access and 
type of healthcare service, type and quantity of diagnostic, laboratory and imag-
ing tests, medical procedures, and medications. Results: A total of 2,035 (91.5%) 
dengue cases were recruited to our study: 1,657 (81.4%) were outpatients and 378 
(18.6%) inpatients; 1,361 (66.9%) were assisted at public and 674 (33.1%) at private 
sector; 398 (19.6%) children and 1,635 (80.4%) adults. Public sector has higher medi-
cal visits average which ranged from 1.2 in Teresina (Northeast) to 4.2 in Goiânia 
(Midwest) for outpatients, and from 3.2 in Goiânia to 5.0 in Teresina for inpatients. 
Hospital length of stay varied from 3-4 days. Full blood count was carried out in 
80% of cases; in 75% of adults, in both outpatients and inpatients. X-ray tests were 
performed in 8.2% of outpatients and 26.2% of inpatients, with most adults (75.0%). 
Frequently outpatients and inpatients reported medication use, 71.0% and 65.9% 
respectively, specially at public sector (75.0%). ConClusions: Our results show 
that HSU patterns of dengue cases have extensive variations regarding healthcare 
sector, severity of illness, and different regions of Brazil. The HSU could be affected 
by dengue clinical guidelines utilized in healthcare service.
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objeCtives: In Germany parallel imports does not only exist due to economic 
reasons like arbitrage principle, but due to special legislative support. According to 
law, pharmacies have to fulfil a predetermined import quota to achieve a certain 
efficiency reserve which should help generating higher savings for the statutory 
health insurance. Prices of imports are only cost efficient if they are fulfilling a 
minimum price difference which is 15% or 15 Euro below the prices of originals. 
The objective is to determine whether imports are price efficient and if they obtain 
the legally implemented savings. Methods: This analysis evaluates data from 
IMS-Database which covers all redeemed GKV receipts. Imports were identified by 
pharmacy number (PZN). Afterwards they were ordered by Anatomical Therapeutic 
Chemical (ATC)-Coding and listed separately for GKV-sales and market share. 
Market share was identified by units sold, sales on basis of manufactures price. 
Prices were taken from a public price list (Lauer-Taxe). For overall savings publi-
cized data were used (Arzneimittel-Atlas). Evaluation period was 2013. Results: 
Imports are focussing on special therapeutics, mainly covering Neurologics (ATC1 
“N”) and Immunsuppressiva (ATC1 “L”). Both indications received a market share 
of 38.7% with sales of 2.5 bio. euro. By looking at the top 5 imports with highest 
sales cost efficient prices according to legal rule are only apparent in 3 of 5 cases 
(absolute rating) and 1 of 5 cases (relative rating). In general, prices of imports are 
oriented to prices of originals and sometimes even excess them. Annual savings 
are 63.5 mio. euro. ConClusions: Imports are focussing on special therapeutic 
areas which mainly lead to high margins for importers. Prices are not efficiently 
according to legal rule so that the expected savings does not result. Therefore 
the existing regulation of import quota should be disestablished. Imports should 
regulate themselves by the competition of the market but without additional 
support by legislation.
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formulary non-adherence and 8 (38.1%) for early refill detection. Only six (28.6%) 
hospitals with PIS have the capability to generate four types of reports(ranking 
physicians by utilization, drug they prescribe, most utilized drug by number of 
patients, most utilized drug by diagnosis). ConClusions: Adopting PIS in Saudi 
hospitals is improving comparing to 2003 study, however, the integration of the 
EMR and CPOE still not to the expected level. To ptimize the institutional Pharmacy 
Benefit Management Program (PBMP), the detection and reporting capabilities of 
the PIS should be improved to facilitate prescribing decision making process, and to 
improve concurrent, prospective, and retrospective drug utilization review process.
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objeCtives: Both the HTA Core Model® (CM) for pharmaceutical evaluations and the 
Academy of Managed Care Pharmacy (AMCP) Format (Format) for formulary submis-
sions were developed to streamline health technology assessment (HTA). The CM is 
specific to European HTAs, while the Format is specific to US managed care. This study 
aims to compare these approaches to identify areas of overlap, and differing elements 
that may reflect regional values and preferences. Methods: The CM for pharmaceu-
ticals (Version 2.1) and the Format (Version 3.1) were examined and analyzed by two 
reviewers. A table of 17 characteristics was created to evaluate which elements align 
or do not align. Results: Of the 17 characteristics, 5 were found to be aligned, 5 were 
somewhat aligned, and 7 were not at all aligned. The CM provides more detailed guid-
ance (388 pages of guidance, 447 pages total) on desired data sources and rationale, 
whereas the Format provides only a short overview of requirements and methodol-
ogy (17 pages of guidance, 95 total). There is general alignment in terms of requiring 
information on burden of disease, existing treatment options, clinical effectiveness, 
and economic analyses, however within these overarching themes, certain variations 
exist. For example, the CM suggests cost-effectiveness, -utility or -benefit analyses, 
while the Format suggests only cost-effectiveness analyses. In addition, the CM con-
tains additional sections, including ethical analysis, organizational aspects, social 
aspects, and legal aspects. Alternatively, the Format contains an addendum specific to 
use of comparative effectiveness research (CER), as defined in the US, stipulating that 
CER studies reflect patient preferences. It also contains a separate addendum specific 
to specialty pharmaceuticals. ConClusions: While the CM and Format require simi-
lar information to be submitted, certain regional values and health system differences 
are reflected in the varying approaches. Trans-Atlantic collaboration could be helpful 
in standardizing characteristics across these frameworks.
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objeCtives: Biologics have made substantial contribution in a number of dis-
eases, but the high cost of therapy in the arena of cost containment impacting 
their accessibility and sustainability. Biosimilars are a viable alternative after patent 
expiry of many first generation originator biologics. Expecting a 20-30% difference 
in price from a branded product, budget impact is being considered an impor-
tant area driving the market access of these products. Hence, we reviewed the 
published budget impact analysis (BIA) of the biosimilars conducted in different 
countries’. Methods: We searched the PubMed, ISPOR, google scholar database 
etc. for English language articles with search terms “budget impact” OR “budget 
analysis” AND “biosimilar” OR “subsequent entry biological” OR “follow-on biologi-
cal”. The methodology of analysis and the major outcomes such as cost saving and 
additional patients treated were reviewed from the included studies. Results: 
Articles reporting the BIA of biosimilars were identified. The studies with BIA were 
segregated based on the countries. The source of funding, model used, and descrip-
tion provided around the model for the BIA was identified. The budget savings 
projected over 2015-2019 ranged from 95.8mn to 433mn at 10% and 30% discount, 
respectively, for UK, Italy, France, and Germany. The net benefit of 29.8mn over 3 
years period resulted in treatment of 1025 to 1615 more patients yearly. ISPOR BIA 
good practice II task force guidance was used to assess the analytical framework, 
data sources, and reporting format. ConClusions: The use of biosimilars seems 
to economically attractive, probably due to cost-savings and additional patients’ 
treatment. However, there is low availability of BIAs for biosimilars, where they 
were introduced long back and/or no availability in countries where just entered the 
market. This potential raises the need for highly robust BIAs, thus, aid in decision-
making for judicious allocation of the budget.
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objeCtives: Healthcare contributes a major proportion of public expenditures. 
The Finnish publicly funded healthcare system consists of primary and secondary 
healthcare services. Currently, specialized healthcare is responsible of 45-55% of 
total healthcare expenditures. The aim was to clarify the current and projected 
future costs for both primary and secondary healthcare. Methods: This register-
based study was performed in a selected area covering approximately 200,000 
inhabitants. The data set consists of 1,55 million healthcare contacts to primary 
or secondary healthcare during 2013. All events were matched to individuals with 
the unique national identification code, in order to obtain the per-patient costs in 
different ages. In the future cost projections, it was assumed the per-patient-costs 
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dence surveillance process was established based on a systematic search of PubMed, 
using key words relevant to economic modelling in healthcare or disease and lim-
ited to studies published in English, in humans, and with abstracts. The surveillance 
incorporated all studies published from 2010 and was updated weekly. Abstracts 
identified by the search of economic evaluation studies were indexed according to 
disease area, using the chapter categorisation from ICD-10 as a framework. Articles 
were also included if they analysed the cost-effectiveness of healthcare service design 
or explored methodological issues related to economic modelling. To account for the 
delay in indexing of publications, we included all studies with a publication date of 
2014 that were indexed in PubMed up to 8 June 2015. Results: The search identified 
2,772 articles published in 2014. Of these, 836 met the inclusion criteria and were sub-
categorised according to topic. The greatest number, 19%, were conducted in patients 
with infectious diseases, with 14% in cancer, 12% in cardiovascular disease, 8% in mus-
culoskeletal disorders, 7% in mental health disorders, 6% in endocrine or metabolic 
disorders and 4% in digestive disorders. A further 7% of identified papers reported 
on modelling methods and 3% on service design. All other disease areas accounted 
for 3% or fewer of the relevant publications per ICD-10 chapter. ConClusions: The 
focus of economic evaluations in 2014 was on infectious diseases, followed by cancer 
and cardiovascular disease. As these three disease areas accounted for almost 60% 
of global mortality in 2012, and cause considerable morbidity, it is encouraging to see 
that health economic research has prioritised finding the most cost-effective ways 
to reduce this burden.
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objeCtives: Since October 2013 HAS is required to provide the inter-ministerial 
pricing committee (CEPS) with an economic evaluation on innovative drugs and 
medical devices likely to have a significant impact on national health insurance 
expenditure. HAS’ evaluation involves a critical appraisal of cost-effectiveness 
analyses (CEA) submitted by manufacturers. Although budget impact analysis 
(BIA) is currently not required by HAS, it may be provided as an optional com-
plement to CEA. Our objective was to assess how BIA was undertaken in manu-
facturers’ submissions. Methods: We used a qualitative approach to assess 
manufacturers’ submissions by end of April 2015 (n= 49). As currently there is 
no formal HAS guideline on BIA, we used the recommendations of the French 
Collège des économistes de la santé as well as ISPOR Task Force Principles on Good 
Practices for BIA as an analytical framework, including perspective, time horizon, 
discounting, size of eligible populations, current comparators, anticipated uptake 
of the new technology, and cost of treatments. Results: Eleven (22%) submissions 
included a BIA along with the CEA. Compliance with ISPOR Task Force principles 
was generally fair for perspective, time horizon and discounting. The selection of 
current comparators was considered problematic in 7 (64%) of these submissions. 
Regarding costs of treatments, the majority of BIA failed to include adverse events 
as well as follow-up costs. In most cases, there was a lack of transparency on BIA 
modelling and eligible population size estimates. Furthermore, in 9 (80%) BIA, sce-
narios were not explored through adequate sensitivity analyses. ConClusions: 
Although based on a small number of submissions, our study identified concerns 
about population size estimates, comparators, identification of costs beyond treat-
ment acquisition and administration, BIA interpretation and scenarios sensitivity 
analyses. This raises the need to include explicit recommendations on BIA in the 
next, updated version of the HAS guideline on economic evaluation.
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objeCtives: In our study we investigated how monetary payment of sick-pay from 
National Health Insurance Fund Administration changed in the analysed period 
according to groups of illnesses. Methods: We used the data of National Health 
Insurance Fund Administration of Hungary and statistical reports of Nr. OSAP 1514, 
as well as data of Hungarian Central Statistical Office from the period between 2005-
2013. At the determination of groups of illnesses we used the main diagnosis of ICD 
classification of diseases. We analysed the following indicators: the number or sick-
pay cases as well as the number of days spent on sick leave with regards to groups 
of illnesses. Results: After having analysed the data we can ascertain that mostly 
musculoskeletal illnesses can be named as reasons for adhering to sick-pay every 
year. (24-28% of all cases) The average time spent on sick-leave in these cases was 
33-41 days. The inflammatory disease of the respiratory system was the second cause 
every year (17-20% of all cases). Resorting to sick-pay because of mental illnesses fell 
from 9 to 5%. The period of sick-leave continuously decreased from 2009. The short-
est, on average 7-18 days of sick-pay was resorted to because of infectious diseases; 
due to the infectious disease of the respiratory system people were on sick-leave for 
12-19 days on average. The period spent on sick-leave because of cancer diseases in 
the investigated years was 55-65 days. ConClusions: Significant decrease occurred 
in the case of days spent on sick-leave due to mental and nervous system diseases 
(2007: 50 days, 3013: 33 days) and inflammatory disease of the respiratory system 
(2005: 19 days, 2013: 12 days).
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objeCtives: The Turkish Medicines and Medical Devices Agency (TMMDA) gives 
permission of unlicensed medicine use by patient basis. Authorized wholesalers 
including Turkish Pharmacists’ Association (TPA) can import the drugs based on 
the TMMDA’s permission. These medicines are reimbursed by the Social Security 
Institution (SSI), the main reimbursement agency in Turkey Until 2014 when 
wholesalers were also authorized, pharmaceuticals under this status could only 
be imported by the Turkish Pharmacists’ Association (TPA The aim of this study is to 
understand the trends in L group (Antineoplastic and immunomodulating agents) 
of ATC classification system unlicensed medicine consumption between 2011 and 
2013 when the TPA was the only authorized supplier. Methods: Consumption 
data of L group in the top 100 imported unlicensed medicines with the highest 
sales share in total expenses of imported off-label use was taken from the TMMDA 
computer database. Descriptive analysis was conducted. Results: The analysis 
showed that the numbers of active ingredients of L group in the top 100 rose from 
37 to 55, between 2011 and 2013. The average cost per box of unlicensed medicines 
in the L group increased from 4.973 TL to 7.436 TL in the same period. The total 
consumption of the unlicensed medicines in L group increased from 107 billion TL 
to 482 billion TL. ConClusions: The cost of imported unlicensed medicines used 
increased every year in Turkey. Some cost-containment measures (especially for 
antineoplastic medicines) should be taken to reduce the increasing cost without 
risking the patients’ access to these innovative medicines.
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objeCtives: The objective of this study was to analyze the costs of septic shock in 
2012 for England, Wales and Northern Ireland. Methods: We analyzed length of stay 
and organ support of 20,549 adult septic shock patients. Septic shock was defined 
as severe sepsis including the presence of cardiovascular organ dysfunction. Data 
derived from the Case Mix Programme Database. This is the national, comparative 
audit of patient outcomes from adult critical care coordinated by the Intensive Care 
National Audit & Research Centre (ICNARC). These analyses were based on data from 
136,880 admissions to 205 adult, general critical care units (CCU) based in NHS hos-
pitals geographically spread across England, Wales and Northern Ireland. Unit costs 
were obtained from the National Schedule of Reference Costs 2012-2013. Results: 
There were 22,081 admissions to CCU, with an average duration of 7.6 days. At a cost 
per day of £1044, this adds up to £175.2 million. There were 14,471 admissions to a 
post-unit discharge location (23.3 days, £240/day). Total ward cost is thus about £80.9 
million. Renal and advanced respiratory support was required by 4,440 and 13,797 
individuals, respectively (both cost £285/day). With an average duration of 5.4 days for 
renal and 7.7 days for respiratory support, the total costs amount to £6.8 million and 
£30.3 million, respectively. Therefore, the total cost of septic shock is estimated to be 
around £293.2 million. ConClusions: With annual costs of nearly £300 million, it 
is evident that septic shock patients pose a heavy burden to the national healthcare 
system. These patients require lengthy hospital stays, as well as substantial renal 
and respiratory support. Adding drug costs, societal costs, as well as Scottish data, 
would increase the total costs even further. Septic shock is a costly disease and every 
effort should be made to reduce this burden to the patients, hospitals and society.
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objeCtives: The role of ‘disinvestment’ in health care, i.e., the withdrawal (partially 
or completely) of interventions that provide no or marginal benefit compared to 
alternative therapeutic approaches is attracting worldwide attention. The objective of 
this study was to identify and review empirical evaluations of disinvestment programs 
to gauge their success and determine key challenges. Methods: We systematically 
searched the medical literature using the PubMed database for empirical evalua-
tions of disinvestment programs using the following search terms; “disinvestment”, 
“resource allocation”, “low value”, and “priority setting”. We did not restrict our search 
in regards to study publication year. Two researchers assessed each identified abstract. 
For each study, we reported the disinvestment program that was assessed and cat-
egorized study findings as ‘successful’ if a reduction in utilization of the low-value 
service was reported, and ‘unsuccessful’ if no reduction in utilization was reported. 
We also reported challenges identified by the study authors in the implementation of 
the disinvestment program. Results: We identified 34 studies describing empirical 
evaluations of disinvestment programs. Fifteen pertained to the National Institute 
for Health and Care Excellence’s recommendations, and/or their ‘do not do list,’ 8 per-
tained to the Choosing Wisely Campaign, and 11 pertained to unique initiatives world-
wide—including the French initiative to delist unnecessary pharmaceuticals with the 
help of its Transparency Commission. The empirical evaluations varied with respect 
to the reported success of the disinvestment programs: twenty-one determined the 
program to be successful, and 13 unsuccessful. Common challenges reported by study 
authors include difficulty in identifying low-value care for disinvestment and gaining 
support among stakeholders. ConClusions: Empirical evaluation of disinvestment 
programs is limited. Available evaluations report varied success for existing disinvest-
ment strategies and noted that a number of key challenges are yet to be overcome.
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objeCtives: To determine the disease focus of all economic evaluation papers 
indexed in the PubMed database that were published in 2014. Methods: An evi-
